On January 9, 2026, Serina Therapeutics, Inc. was notified that it does not meet the NYSE American's minimum stockholders' equity requirement of $2 million, having only $1.6 million as of September 30, 2025. The company has until February 8, 2026, to submit a plan to regain compliance within 18 months or face potential delisting.